Molecular and Cellular Pathobiology RHPN 2 Drives Mesenchymal Transformation in Malignant Glioma by Triggering RhoA Activation

Mesenchymal transformation is a hallmark of aggressive glioblastoma (GBM). Here, we report the development of an unbiased method for computational integration of copy number variation, expression, and mutation data from large datasets. Using this method, we identified rhophilin 2 (RHPN2) as a central genetic determinant of the mesenchymal phenotype of human GBM. Notably, amplification of the human RHPN2 gene on chromosome 19 correlates with a dramatic decrease in the survival of patients with glioma. Ectopic expression of RHPN2 in neural stem cells and astrocytes triggered the expression of mesenchymal genes and promoted an invasive phenotype without impacting cell proliferation. Mechanistically, these effects were implemented through RHPN2-mediated activation of RhoA, amaster regulator of cell migration and invasion. Our results define RHPN2 amplification as a central genetic determinant of a highly aggressive phenotype that directs the worst clinical outcomes in patients with GBM. Cancer Res; 73(16); 1–11. 2013 AACR.

[1]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[2]  Antonina Silkov,et al.  Genome-wide functional annotation of dual-specificity protein- and lipid-binding modules that regulate protein interactions. , 2012, Molecular cell.

[3]  M. El-Sibai,et al.  Rho GTPases in primary brain tumor malignancy and invasion , 2012, Journal of Neuro-Oncology.

[4]  Ganesh Rao,et al.  The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. , 2011, Genes & development.

[5]  J. Sarkaria,et al.  Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans. , 2011, The Journal of clinical investigation.

[6]  M. Haenle,et al.  Rare phenomenon: liver metastases from glioblastoma multiforme. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Brennan,et al.  Molecular subclassification of diffuse gliomas: Seeing order in the chaos , 2011, Glia.

[8]  Torbjörn E. M. Nordling,et al.  Network modeling of the transcriptional effects of copy number aberrations in glioblastoma , 2011, Molecular systems biology.

[9]  H. Rugo,et al.  Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Pe’er,et al.  An Integrated Approach to Uncover Drivers of Cancer , 2010, Cell.

[11]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[12]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[13]  J. Uhm,et al.  The transcriptional network for mesenchymal transformation of brain tumours , 2010 .

[14]  Dana Pe'er,et al.  JISTIC: Identification of Significant Targets in Cancer , 2010, BMC Bioinformatics.

[15]  J. Uhm.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .

[16]  A. Krasnitz,et al.  An Oncogenomics-Based In Vivo RNAi Screen Identifies Tumor Suppressors in Liver Cancer , 2008, Cell.

[17]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[18]  Pan Du,et al.  lumi: a pipeline for processing Illumina microarray , 2008, Bioinform..

[19]  A. Ridley,et al.  Rho GTPases in cancer cell biology , 2008, FEBS letters.

[20]  Y. Kloog,et al.  A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. , 2006, Cancer research.

[21]  B. André,et al.  Rhophilin-2 is targeted to late-endosomal structures of the vesicular machinery in the presence of activated RhoB. , 2006, Experimental cell research.

[22]  Howard Y. Chang,et al.  Genetic regulators of large-scale transcriptional signatures in cancer , 2006, Nature Genetics.

[23]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[24]  R. Sidman,et al.  Expression profile of an operationally-defined neural stem cell clone , 2005, Experimental Neurology.

[25]  S. Horvath,et al.  Gene Expression Profiling of Gliomas Strongly Predicts Survival , 2004, Cancer Research.

[26]  M. Westphal,et al.  Cost of migration: invasion of malignant gliomas and implications for treatment. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  P. Burbelo,et al.  The RhoA-binding protein, Rhophilin-2, Regulates Actin Cytoskeleton Organization* , 2002, The Journal of Biological Chemistry.

[28]  E. Sahai,et al.  RHO–GTPases and cancer , 2002, Nature Reviews Cancer.

[29]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[30]  Michael D Schaller,et al.  Paxillin: a focal adhesion-associated adaptor protein , 2001, Oncogene.

[31]  S. Narumiya,et al.  Cofilin phosphorylation by protein kinase testicular protein kinase 1 and its role in integrin-mediated actin reorganization and focal adhesion formation. , 2001, Molecular biology of the cell.

[32]  H. Sontheimer,et al.  Role of lysophosphatidic acid and rho in glioma cell motility. , 2000, Cell motility and the cytoskeleton.